Page 184 - 2021_04-Haematologica-web

I. Abou Dalle et al.
Targeted therapy was added by the treating physicians (alternating cycles of hyperfractionated cyclophos- when indicated (Online Supplementary Table S1 includes phamide, vincristine, doxorubicin, dexamethasone and mutations identified in the AML matched cohorts). methotrexate and cytarabine) or Augmented Berlin– Patients in the ALL cohorts received either HyperCVAD Frankfurt–Münster (AugBFM) regimens.21
Figure 2. Long-term peripheral blood count recovery following chemotherapy with and without leuprolide. Scatterplots of all corresponding peripheral blood labo- ratory data extracted from health records, collected after induction chemotherapy (day 0) where each dot represents a single value (blue for leuprolide, red for con- trol). (A-B) Change in absolute neutrophil count. (C-D) Change in absolute lymphocyte count. (E-F) Change in platelet count. Lowess smooth curves were used for indi- cating longitudinal trajectories of counts and differences were assessed using the generalized estimation equation model. AML: acute myeloid leukemia; ALL: acute lymphoblastic leukemia.
AB
CD
EF
1100
haematologica | 2021; 106(4)